Maple Leaf Green World (TSXV:MGW; OTCQB:MGWFF) announces, further to its press release dated June 20, 2017, that the Company and BioNeva Innovations of Henderson LLC (“BioNeva”) have jointly submitted a Medical Marijuana Establishment Certificate (the “Nevada Permit”) transfer application (the “Transfer Application”) to the City of Henderson, Nevada , pursuant to which officials from the City of Henderson will consider the transfer of the Nevada Permit from BioNeva to the Company. The Transfer Application includes the requisite documents for such application, including architectural blueprints prepared by a U.S. architecture company for Maple Leaf’s proposed cannabis production site in the City (the “Nevada Site”).
A staff review panel at the City of Henderson (the “Staff Panel”) will review and comment on the Transfer Application, including making suggested changes to the proposed design for the Nevada Site. The review is expected to take place between now and the early part of August when the City Council for the City of Henderson (the “Council”) plans to meet and consider cannabis permit matters. The Company understands that it and BioNeva will have sufficient time to make any suggested changes from the Staff Panel before the Transfer Application is presented to the Council for approval. Once approved by the Council, the Company expects to commence ordering materials and securing construction contracts for development on the Nevada Site. The Company still expects to finish construction of the Nevada Site by the end of 2017.
The Company retains Big Reach Media, Inc. as its Investors Relations Advisor
The Company also announces that it has entered into an investor relations agreement (the “Investor Relations Agreement”) with Big Reach Media, Inc. (“Big Reach”) whereby Big Reach will provide certain services to Maple Leaf that may be considered investor relations and promotional activities on behalf of Maple Leaf which require disclosure in this press release pursuant to the policies of TSX Venture Exchange (the “TSXV”).
Subject to the approval of the TSX Venture Exchange (the “TSXV“), the terms of the Investor Relations Agreement provide that the Company will pay Big Reach a monthly fee of $5,000. The term of the Investor Relations Agreement commences August 1, 2017 and is for an initial term of 6 months. At the end of the initial term, Maple Leaf and Big Reach may agree to extend the engagement on a month to month basis for a fee of $5,000 per month.  
For further information regarding Maple Leaf Green World Inc., please visit www.mlgreenworld.com.
 
About Maple Leaf Green World Inc.
Maple Leaf is a public Canadian company that focuses on the cannabis industry in North America. The Company currently operates 3 cannabis projects in British Columbia, California, and Nevada. With over 10 years of extensive greenhouse management experience, it applies its eco-agriculture knowledge and cultivation technology to produce contaminant-free organic cannabis products. Maple Leaf’s long-term objective is to produce cannabis oil and export its products to approved countries.
 
Cautionary Statement
This press release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable Canadian securities legislation. Specifically, this press release includes, but is not limited to, forward-looking statements with respect to the review of the Transfer Application and the timing thereof, timing with respect to making any suggested changes from the Staff Panel before the Transfer Application is presented to the Council for approval, the approval of the transfer of the Nevada Permit to Maple Leaf, the construction of the Nevada Site and the timelines thereof, and the anticipated approvals of the Investor Relations Agreement and renewal of the terms thereunder. Generally, forward-looking statements can be identified by the forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “projects”, “intends”, “anticipates”, or “does not anticipate”, or “believes”, or “variations of such words and phrases or state that certain actions, events or results “may”, “can”, “could”, “would”, “might”, or “will” be taken”, “occur” or “be achieved”. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause the actual results, level of activity, performance, or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the development and operation of the Company’s projects, risks associated with general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments involving medical cannabis, inability to access sufficient capital from internal and external sources and/or inability to access sufficient capital on favourable terms, the medical cannabis industry in Canada and the jurisdictions where the Company operates generally, including Nevada, income tax and regulatory matters, competition, crop failure, currency and interest rate fluctuations, regulatory approvals including approvals from the Council of the Company’s Transfer Application, and those factors discussed in the sections relating to risk factors of our business filed in the Company’s required securities filings on SEDAR. Although the Company has attempted to identify important factors that could cause results to differ materially from those contained in forward-looking statements, there may be other factors that cause results to be materially different from those anticipated, described, estimated, assessed or intended. There can be no assurance that any forward-looking statements will prove accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements that are incorporated by reference herein, except in accordance with applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
 
 
For further information, please contact:
Maple Leaf Green World Inc.
Raymond Lai, Chairman, President & CEO
+1(403) 452-4552
+1(403) 452-6900
rlai@mlgreenworld.com www.mlgreenworld.com
 
Big Reach Media, Inc. (Investor Relations)
Dale Shirley
Phone: (780) 632-6963
Mobile: (780) 964-4732
dale@bigreachmedia.com
http://www.bigreachmedia.com/
Click here to connect with Maple Leaf Green World (TSXV:MGW; OTCQB:MGWFF) to receive an Investor Presentation.

Source: www.newswire.ca


PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Chemesis International Inc. (the “Company”) (CSE:CSI)(OTCQB:CADMF)(FRA:CWAA

The Company announces that its (former) subsidiary, Natural Ventures PR, LLC (“NVPR”), has sold all of its cannabis assets, and assigned all related liabilities, licenses and permits, to Puerto Rico Industrial Commercial Holdings Biotech Corp. (“PRICH”) in exchange for immediate net cash proceeds to the Company, in respect of its 80% interest in NVRP, of US$450,000. The Company notes that, in connection with, and as a condition to, this transaction, it will cease to be a shareholder of NVPR.

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less